This article is more than 5 years old. Information may no longer be current.

Allergan receives FDA approval for new entry in breast implant line

Allergan received approval from the FDA to market the Natrelle Inspira Cohesive breast implants, according to a press release.

The Natrelle Inspira Cohesive line is a part of a newer category of breast implants commonly referred to as “gummy” implants, according to the release. The implants offer a shaping option for women undergoing reconstruction, augmentation or revision surgery that combines a high gel fill ratio and Allergan’s cohesive gel for customizable results.

“Natrelle Inspira Cohesive breast implants are just the latest examples of our commitment to innovation in breast aesthetics and plastic surgery, and we are proud that we are able to continue to offer advancements in technology that allow physicians and their patients more options,” David Nicholson, chief research and development officer of Allergan, said in the release.

The Natrelle Inspira Cohesive breast implants are available with both smooth and Biocell textured surfaces.